On 2 June 2021, the antibody-drug combination by the US drugmaker Eli Lilly was granted EUA in India. This combination was permitted for the treatment of mild to moderate COVID -19 in India.
The monoclonal antibody drugs, bamlanivimab 700 mg, and etesevimab 1400 mg, have received permission for restricted use. Eli Lilly has stated that these two drugs are used together for treating mild to moderate patients. 
The company is in talks with the Indian government and regulatory authorities to donate these two drugs to India. By doing so, the drug firm hopes to speed up access and provide treatment to all the patients in the country.
Bamlanivimab and etesevimab: This antibody combination has also received the EUA in the US and some European Union countries for treating COVID – 19.
In May 2021, Eli Lilly had received permission for the emergency use of barcitinib in combination with remdesivir. This combination was permitted for treating suspected or laboratory – confirmed COVID – 19 in India.
Abbreviations : 1. Emergency Use Authorization
- Monthly Update- pharma News July 2021
- Moderna collaborates with Thermo Fischer Scientific
- Bamlanivimab and Etesevimab: EUA in India
- JB Chemicals launches NOSMOK nicotine lozenges
- 2-DG: anti-COVID-19 by the INMAS
- GSK and Vir Biotechnology plan to launch Sotrovimab
- USFDA approves Gland Pharma’s Foscarnet
- Gilead delivers Amphotericin B to India
- Monthly Update- pharma News June 2021
- Zydus seeks DCGI’s approval for COVID-19 biological therapy
- Zydus and TLC to commercialize AmphoTLC in India
- Sun Pharma recalls Metformin tablets from the US market
- Pfizer – BioNTech pledge to supply 2 billion doses
- Johnson & Johnson COVID Vaccine update
- Jubilant, Sun, and Lupin initiated products recall